Lower Dose Orexin Inhibitors for Insomnia Treatment

Introduction to Lower Dose Orexin Inhibitors

The American Academy of Internal Medicine recommends lower dose orexin inhibitors like suvorexant (Belsomra) at 5-10 mg as a second-line treatment option for insomnia when cognitive behavioral therapy is unsuccessful, offering improved safety profiles while maintaining efficacy for sleep maintenance 1

The American College of Physicians suggests that first-line treatment should always begin with cognitive behavioral therapy for insomnia (CBT-I), and pharmacotherapy should only be considered when CBT-I alone is unsuccessful 1

No dose adjustment is needed for advanced age, according to the American Geriatrics Society, as stated in the Annals of Internal Medicine 1

The American Academy of Sleep Medicine (AASM) suggests that clinicians use suvorexant as a treatment for sleep maintenance insomnia in adults, based on trials of 10, 15/20, and 20 mg doses 2, 3, 4
Compared to placebo, suvorexant improves total sleep time by approximately 10 minutes and reduces wake after sleep onset by 16-28 minutes 5, 6

The most common adverse effect of suvorexant is somnolence, occurring in approximately 7% of patients (vs 3% for placebo) 6, 7
FDA labeling warns of potential cognitive and behavioral changes, including amnesia, anxiety, hallucinations, and other neuropsychiatric symptoms 7

The American Academy of Sleep Medicine suggests that patients on suvorexant 3mg and lemborexant 10mg during zopiclone weaning may benefit from increasing the suvorexant dose to 10-15mg while continuing lemborexant 10mg, as this combination provides superior wake-after-sleep-onset reduction compared to either agent alone at current doses 8
The current regimen of suvorexant 3mg and lemborexant 10mg, with concurrent weaning off zopiclone 3.75mg, has improved sleep initiation but not sleep maintenance, according to the American Academy of Sleep Medicine 8, 9

The American Academy of Sleep Medicine recommends that suvorexant's efficacy for sleep maintenance is dose-dependent, with a current 3mg dose being subtherapeutic for sleep maintenance 10
Clinical trials show that suvorexant is effective at 10mg, 15/20mg, and 20mg doses, and at therapeutic doses, suvorexant reduces wake after sleep onset by 16-28 minutes compared to placebo, as reported by the American Academy of Sleep Medicine 8
The American Academy of Sleep Medicine suggests that adding low-dose doxepin (3-6mg) can provide strong evidence for sleep maintenance, with a mean wake after sleep onset reduction of 22-23 minutes 8, 10

The American Academy of Sleep Medicine recommends monitoring for potential side effects, including somnolence, headache, and nightmares, when using dual orexin receptor antagonists 8